ACP 204
Alternative Names: ACP-204Latest Information Update: 08 Aug 2025
At a glance
- Originator ACADIA Pharmaceuticals
- Class Antidementias; Antipsychotics; Behavioural disorder therapies
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Psychotic disorders
- Phase II Lewy body disease
Most Recent Events
- 31 Jul 2025 ACADIA Pharmaceuticals plans a phase III trial for Lewy body disease (PO, Capsule) in August 2025 (NCT07095465) (EudraCT2025-521711-39-00)
- 27 Jul 2025 Efficacy and pharmacokinetics data from a phase I trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2025 (AAIC-2025)
- 27 Jul 2025 Pharmacodynamics and pharmacokinetics data from preclinical trials in Psychotic disorders presented at the Alzheimer's Association International Conference 2025 (AAIC-2025)